Comments on the MRC/BHF Heart Protection Study

Comment

Christoph Pechlaner. Lancet. 2003.

. 2003 Aug 30;362(9385):744; author reply 744-5.

doi: 10.1016/S0140-6736(03)14211-0.

No abstract available

Comment on

MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial.
Collins R, Armitage J, Parish S, Sleigh P, Peto R; Heart Protection Study Collaborative Group. Collins R, et al. Lancet. 2003 Jun 14;361(9374):2005-16. doi: 10.1016/s0140-6736(03)13636-7. Lancet. 2003. PMID: 12814710 Clinical Trial.

Comments on the MRC/BHF Heart Protection Study.
Mikhail N. Mikhail N. Lancet. 2003 Aug 30;362(9385):744; author reply 744-5. doi: 10.1016/S0140-6736(03)14212-2. Lancet. 2003. PMID: 12957101 No abstract available.
Comments on the MRC/BHF Heart Protection Study.
Sirtori CR. Sirtori CR. Lancet. 2003 Aug 30;362(9385):744; author reply 744-5. doi: 10.1016/S0140-6736(03)14213-4. Lancet. 2003. PMID: 12957102 No abstract available.
Comments on the MRC/BHF Heart Protection Study.
Abramson J. Abramson J. Lancet. 2003 Aug 30;362(9385):745-6. doi: 10.1016/S0140-6736(03)14215-8. Lancet. 2003. PMID: 12957104 No abstract available.
Beta receptor blocking agents in the secondary prevention of coronary heart disease.
Vedin JA, Wilhelmsson CE. Vedin JA, et al. Annu Rev Pharmacol Toxicol. 1983;23:29-44. doi: 10.1146/annurev.pa.23.040183.000333. Annu Rev Pharmacol Toxicol. 1983. PMID: 6135389 Review. No abstract available.
The TFOS International Workshop on Contact Lens Discomfort: report of the subcommittee on clinical trial design and outcomes.
Foulks G, Chalmers R, Keir N, Woods CA, Simpson T, Lippman R, Gleason W, Schaumberg DA, Willcox MD, Jalbert I; members of the TFOS International Workshop on Contact Lens Discomfort. Foulks G, et al. Invest Ophthalmol Vis Sci. 2013 Oct 18;54(11):TFOS157-83. doi: 10.1167/iovs.13-13189. Invest Ophthalmol Vis Sci. 2013. PMID: 24058132 No abstract available.